Exelixis Inc Stock Price, News & Analysis

Exelixis (Nasdaq: EXEL) and Natera (Nasdaq: NTRA) announced a collaboration on STELLAR-316, a planned randomized Phase 3 pivotal trial of oral kinase inhibitor zanzalintinib in resected stage II/III colorectal cancer (CRC) patients who are molecular residual disease (MRD)-positive.

The trial will use Natera’s Signatera assay to identify MRD-positive patients and for longitudinal circulating tumor DNA monitoring. The primary endpoint is disease-free survival. Exelixis expects to initiate STELLAR-316 in mid-2026. The release cites a projected 2035 incidence of ~89,000 stage II/III CRC cases, with ~20% expected to remain MRD-positive after definitive therapy.

Exelixis (NASDAQ: EXEL) announced that Michael M. Morrissey, Ph.D., president and CEO, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET.

The presentation will be webcast and accessible via www.exelixis.com under the Event Calendar on the Investors & News page. A replay will be available at the same location for at least 30 days.

Exelixis (NASDAQ: EXEL) will webcast a virtual 2025 R&D Day titled Building Next-generation Oncology Franchises on Wednesday, December 10, 2025 from 1:00 p.m. to 3:30 p.m. EST. Featured speakers will review Exelixis' R&D progress and outline the company strategy to advance future oncology franchises, with a focus on raising standards of care and generating long-term shareholder value.

The live webcast and a recording will be available at EXELRDDay.com and on the company Event Calendar at exelixis.com under Investors & News; content will remain accessible for one year. Registration uses code EXELR&D; participants are encouraged to register in advance for timely access.

Exelixis (NASDAQ: EXEL) announced that management will participate in fireside chats at two investor conferences in November with live webcasts and replays.

Schedule: Guggenheim Healthcare Innovation on Monday, November 10, 2025 at 10:30 a.m. ET / 7:30 a.m. PT in Boston; Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:40 a.m. ET / 5:40 a.m. PT in New York City. Webcasts and replays will be available via the company's Event Calendar at www.exelixis.com for at least 30 days.

Exelixis (Nasdaq: EXEL) reported Q3 2025 total revenues of $597.8M and cabozantinib U.S. net product revenues of $542.9M. GAAP diluted EPS was $0.69 and non-GAAP diluted EPS was $0.78. The company announced an additional $750M stock repurchase program to be completed by the end of 2026 and updated 2025 guidance with total revenues of $2.30B–$2.35B and net product revenues of $2.10B–$2.15B. Exelixis plans to submit a U.S. NDA for zanzalintinib by year-end after positive STELLAR-303 OS results; CABOMETYX approvals for NETs were expanded in 2025 in the U.S., EU, Brazil and Australia. Restructuring charges and guidance changes were also disclosed.

Exelixis (Nasdaq: EXEL) will release third quarter 2025 financial results on Tuesday, November 4, 2025 after markets close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT to discuss results and provide a business update.

Investors can access the event via the company website. Telephone access requires registration, which provides a dial-in number and unique PIN. A webcast replay will be archived on the company website for one year.

Exelixis (NASDAQ: EXEL) reported detailed Phase 3 STELLAR-303 results for zanzalintinib + atezolizumab in previously treated non‑MSI‑high metastatic colorectal cancer presented at ESMO 2025 and published in The Lancet. In the ITT population the combination reduced risk of death by 20% (stratified HR 0.80; 95% CI 0.69–0.93; P=0.0045) with median OS 10.9 months versus 9.4 months for regorafenib at 18.0‑month follow‑up. PFS trended favorably (HR 0.68; median 3.7 vs 2.0 months). Safety showed higher grade 3/4 AEs (59% vs 37%) and modestly higher discontinuations. Exelixis plans a U.S. NDA submission in 2025.

Exelixis (NASDAQ: EXEL) reported subgroup results from the CABINET phase 3 trial showing CABOMETYX (cabozantinib) markedly improved outcomes in previously treated advanced lung or thymic neuroendocrine tumors (NET).

In 49 patients with lung or thymic NET, CABOMETYX reduced risk of progression or death by 81% vs placebo (HR 0.19; 95% CI 0.06-0.54; one-sided P=0.0003) with median PFS 8.2 months vs 2.7 months. Confirmed objective response rates were 6% vs 0%. Safety was consistent with known profile; most frequent grade 3/4 events: fatigue 24%, hypertension 18%, diarrhea 9%, palmar plantar erythrodysesthesia 9%.

U.S. FDA approvals in March 2025 and European Commission approval in July 2025 were noted.

Exelixis (Nasdaq: EXEL) has appointed Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development. Dr. Aftab, a 25-year veteran of the company, will oversee all aspects of drug discovery, translational research, product development, and medical affairs activities.

Dr. Aftab has been instrumental in the discovery and development of CABOMETYX® (cabozantinib), the leading tyrosine kinase inhibitor in the U.S. for advanced renal cell carcinoma and advanced neuroendocrine tumors. Previously serving as Executive Vice President, Discovery and Translational Research and Chief Scientific Officer since December 2022, he will now lead the development of zanzalintinib and the company's early-stage pipeline.